October 23, 2014 | Beta-O2 Technologies announced that the company’s first broad study of the ßAir Bio-Artificial Pancreas has been successfully implanted. ßAir is a treatment still under development for Type I diabetes, with hope that it may even be a cure. The eight participants in the study will be treated and observed at Uppsala University Hospital in Sweden. According to Beta-O2 chairman, if the eight-person trial is successful, it will be necessary to carry out an efficacy trial on an addition 50 patients, after which it will be possible to market the product. Beta-O2 was founded in 2004 and is headquartered in Rosh HaAyin, Israel.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
September 05, 2024
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
September 05, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
September 04, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Nonprofit Launches Loans For Stricken Northern Israel Businesses
September 04, 2024
Facebook comments